Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1105-1112

  Uhlenhake, Elizabeth E ^a   Feldman, Steven R ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Enbrel; Interleukin 12; Interleukin 23; Psoriasis treatments; Tumor necrosis factor alpha inhibitor

Indexed keywords

ETANERCEPT; PLACEBO; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTHRALGIA; BASAL CELL CARCINOMA; CARDIOVASCULAR RISK; CELLULITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DEMYELINATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEPATITIS B; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SALMONELLOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; STROKE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953335497     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.487061     Document Type: Review

References (65)

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-17
2. Lebwohl M. Psoriasis. Lancet 2003;361:1197-1204
3. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-1912
4. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-694
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407
6. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, IFN-gamma, IL-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type I differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-759
7. Bos JD, Hulsebosch HJ, Krieg SR, et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-189
8. Steinman L. A rush to judgment on Th17. J Exp Med 2008;205:1517-1522
9. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23
10. Vanden Eijnden S, Goriely S, De Wit D, et al. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated nave T cells in human. Eur J Immunol 2005;35:469-475
11. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29:210-214
12. Liu H and Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008;180:7948-7957
13. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949
14. Hehlgans T, Pfeffer K. The intriguing biology of tumor necrosis factor/tumor necrosis factor receptor superfamily: players, rules, and the games. Immunology 2005;115:1-20
15. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple pro-inflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-2729
16. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194
17. Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111:1053-1057
18. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriatic lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-1915
19. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-290
20. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-1068
21. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/ 23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 2008;144:200-207
22. Krueger GG, Langely RG, Leonardi C, et al. A human interleukin-12/ 23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592
23. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and Safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674
24. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684
25. Griffiths CEM, Strober BF, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-128
26. Kasper LH, Everitt D, Leist T, et al. Safety, pharmacokinetic, and biological response profile of an IL-12p40 antagonist in MS: a phase I clinical trial. Proc Congress Eur Committee Treat Res Mult Scler 2004;107-115
27. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-1044
28. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double blind, placebo-controlled study evaluating single subcutaneous administration of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23:1081-1092
29. O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biol Targets Ther 2009;3:159-168
30. Toichi E, McCormick TS, Kaufmann CL, et al. Quantitation of cutaneous cytokine mRNA levels following anti-IL-12 psoriasis therapy: identification of a psoriasis subset. J Invest Dermatol 2003;121:1249
31. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptordeficient patients. Science 1998;280(5368):1435-1438
32. Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12 and IFN-gamma-mediated immunity: a molecular genetics update. Mol Immunol 2002;38(12-13):903-909
33. Niemann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835 (Pubitemid 44556851)
34. Gelfand JM, Neiman AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741
35. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-164
36. Enbrel (etanercept) [package insert]. Thousand Oaks, Calif: Amgen Inc and Wyeth-Ayerst Pharmaceuticals; 2006
37. Van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-1185
38. Ortonne J-P, Griffiths C, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54weeks: the CRYSTEL study. Exp Rev Dermatol 2008;3:657-665
39. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006;367:29-35
40. de Vlam K, Lories RJU. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006;45:321-324
41. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632
42. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390
43. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022
44. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-1312
45. Mease P, Kivitz A, Burch F, et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial. Arthritis Rheum 2001;44:S90
46. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-251
47. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-772
48. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double-blind multicentre trial. BMJ 2010;340:c147
49. Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-861
50. Driessen RJB, Bowzeman JB, van de Kerkhof PCM, de Jong EMGJ. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009;160:670-675
51. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147
52. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-486
53. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259
54. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-1192
55. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006;54:160-164
56. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138:686-688
57. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502
58. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-181
59. Keystone EC. Safety of biologic therapies-an update. J Rheumatol Suppl 2005;74:8-12
60. Hannuksela-Svahn A, Pukkala E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-590
61. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-128
62. Sokka T. Rheumatoid arthritis databases. Rheum Dis Clin North Am 2004;30:769-781
63. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006;20:370-379
64. Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-414
65. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermaol Symp Proc 2004;9:136-139